Alaunos Therapeutics (TCRT) Q2 2026 earnings summary

Executive summary

• No product revenue generated; significant net losses continue, with a $1.9 million net loss for the six months ended June 30, 2026, and an accumulated deficit of $926.6 million since inception in 2003.

• Focus is on advancing a preclinical, oral small-molecule program (ALN1003) for obesity and metabolic disorders, with promising preclinical results in mouse models.

• Recent preclinical studies show ALN1003 produces dose-dependent weight loss, improved metabolic biomarkers, and favorable liver histology in diet-induced obesity mouse models.

• Company faces substantial doubt about its ability to continue as a going concern due to limited cash resources and lack of committed capital.

Financial highlights

• Cash and cash equivalents were $0.12 million as of June 30, 2026, down from $1.39 million at December 31, 2025.

• Net loss for the three months ended June 30, 2026, was $952,000, compared to $1.05 million for the same period in 2025.

• Net loss for the six months ended June 30, 2026, was $1.96 million, compared to $2.12 million for the same period in 2025.

• Research and development expenses increased 110% year-over-year for the quarter, while general and administrative expenses decreased 34%.

• Stockholders' equity was $652,000 as of June 30, 2026, below the Nasdaq minimum requirement.

Outlook and guidance

• Cash runway is expected to fund operations only into the third quarter of 2026 at the current monthly burn rate of $0.21 million.

• Advancement of ALN1003 into IND-enabling studies is contingent on securing additional capital.

• The company is actively seeking strategic financing, collaborations, or licensing to support continued development.